Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.40 |
| ▸ | CNR1 | P21554 | 11/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27291640 | 0.80 | GSTP1 (0.47) | CNR2CNR1GSTP1FFAR1 | |
| SCHEMBL30689426 | 0.80 | CNR2 (0.41) | CNR2CNR1GSTP1FFAR1 | |
| SCHEMBL31527956 | 0.79 | GSTP1 (0.43) | CNR2CNR1GSTP1FFAR1 | |
| SCHEMBL30689306 | 0.78 | GSTP1 (0.39) | CNR2CNR1GSTP1FFAR1 | |
| SCHEMBL30689397 | 0.75 | AKR1B1 (0.39) | CNR2CNR1GSTP1FFAR1 | |
| SCHEMBL30689442 | 0.74 | GSTP1 (0.41) | CNR2CNR1GSTP1FFAR1 | |
| SCHEMBL30689300 | 0.74 | GSTP1 (0.45) | GSTP1FFAR1 | |
| SCHEMBL30689419 | 0.73 | FFAR1 (0.53) | GSTP1FFAR1 | |
| SCHEMBL31527931 | 0.71 | MAPT (0.42) | GSTP1 | |
| SCHEMBL30689425 | 0.71 | MAPT (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543875-A1 | OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES | Sitryx Therapeutics Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023247958-A1 | OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-28 | — | — | WO | disclosed |